



HAND DELIVERED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: McGee *et al.*

Confirmation No.: 7972

Application No.: 10/810,325

Art Unit: 1625

Filed: March 25, 2004

Examiner: Seaman, D. Margaret M.

For: COMPOUNDS FOR THE MODULATION OF  
PPAR $\gamma$  ACTIVITY

Attorney Docket No: 11134-123-999  
(CAM: 893053-999123)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 AND 1.97**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

References A01-A17 are U.S. patents and published patent applications. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Legible copies of References B01-B48, and C01-C10 are submitted herewith.

Reference (B04) WO 98/37061 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 98/37061, which can be found on the face page of the document. The abstract describes aryl sulfonamides and analogues thereof, methods for producing same and their use in the treatment of neurodegenerative diseases.

Reference (B06) WO 99/00372 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 99/00372, which can be found on the face page of the document.

01/02/2009 AWONDAF2 00000130 503013 10810325  
01 FC:1006 180.00 DA

The abstract describes sulfonamide compounds useful in treating diseases curable based on the hypoglycemic effect, and diseases curable based on the cGMP-PDE inhibitory, leiolytic, bronchodilating, vasodilating, smooth muscle cell inhibitory, and antiallergic effects.

Reference (B10) WO 00/10967 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 00/10967, which can be found on the face page of the document. The abstract describes aryl sulphonamides and analogues, methods for the production and use thereof in the prophylaxis and treatment of neurodegenerative diseases.

Reference (B11) WO 00/10968 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 00/10968, which can be found on the face page of the document. The abstract describes aryl sulphonamide amino acid esters and analogues, methods for the production and use thereof in the prophylaxis and treatment of neurodegenerative diseases.

Reference (B12) WO 00/31021 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 00/31021, which can be found on the face page of the document. The abstract describes compounds, salts or prodrugs of the same which inhibit β-amyloid protein production/secretion.

Reference (B15) WO 02/051397 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 02/051397, which can be found on the face page of the document. The abstract describes cytokine production inhibitors containing as the active ingredient aniline derivatives represented by the general formula (I) or salts thereof.

Reference (B16) WO 02/051820 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 02/051820, which can be found on the face page of the document. The abstract describes compounds, salts and drugs for controlling peroxisome proliferation-activated receptor which contain the compounds as active ingredients.

Reference (B34) WO 02/13864 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 02/13864, which can be found on the face page of the document.

The abstract describes medicinal compositions for preventing or treating cancer, wherein one or more PPAR $\gamma$  activation agonists and one or more RXR activation agonists are used simultaneously or successively.

Reference (B35) WO 02/14291 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 02/14291, which can be found on the face page of the document. The abstract describes compounds, salts, and activators of PPAR  $\delta$  containing the compounds and salts as the active ingredient.

Reference (B47) WO 02/46161 is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the English language abstract of WO 02/46161, which can be found on the face page of the document. The abstract describes substituted carboxylic acid derivatives which bind as a ligand to human peroxisome proliferator activated receptor (PPAR) to activate the receptor; and a process for preparing the derivatives.

Applicants respectfully request that the Examiner review the references and that the references be made of record in the file history of the application.

Identification of references listed on the attached List of References Cited by Applicant is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application. The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is to be charged to Jones Day Deposit Account No. 50-3013.

Information Disclosure Statement Under 37 CFR §§ 1.56 AND 1.97  
Application No. 10/810,325

The Commissioner is authorized to charge any fee required or credit any overpayment for this Information Disclosure Statement to Jones Day Deposit Account No. 50-3013 (order no. 893053-999123).

Date: December 30, 2008

Respectfully submitted,

  
David C. Pauling

42,983

For: Anthony M. Insogna

(Reg. No.)

(Reg. No. 35,203)

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

